Cambridge Healthtech Institute’s 11th Annual

Kinase Inhibitor Chemistry

April 14-15, 2020




Kinase inhibitor discovery is a very active area as developers are exploring more deeply into designing immune-modulatory agents as single or combination therapies, tackling chronic disease indications, such as inflammation and CNS disorders, as well as effectively harnessing allosteric modulators, and covalently binding compounds. This year will also be discussing the role of artificial intelligence, RNAs as drug targets, phosphatases, and protein degraders in kinase development. Cambridge Healthtech Institute’s 11th Annual Kinase Inhibitor Chemistry conference will once again bring together academic and industry leaders to network, collaborate and discuss advances in kinase inhibitor discovery and development.


Preliminary Agenda

NEW TARGETS & PROMISING CANDIDATES

Targeted Therapy in Patients with PIK3CA-Related Overgrowth Syndrome

Guillaume Canaud, MD, PhD, Professor of Medicine, Hospital Necker Enfants Malades, Paris

Comprehensive Evaluation of CDK Inhibitor Landscape in Cells

Carrow Wells, Research Associate, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

A Cdk9-PP1 Switch Regulates the Elongation-Termination Transition of RNA Polymerase II

Pabitra Parua, PhD, Research Fellow, Robert P. Fisher Lab, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai

Interfering with the Immune System: DMXD-011, a Potential Treatment for Systemic Lupus Erythematosus (SLE)

Trevor Perrior, MA, PhD, FRSC, CEO, Domainex Limited

NEW TOOLS AND STRATEGIES

Artificial Intelligence in Kinase Inhibitor Discovery 

Istvan J. Enyedy, PhD, Principal Scientist, Biogen

Discovery of Brain-Penetrant ASK1 Inhibitors for the Treatment of Neurological Diseases

Felix Gonzalez Lopez de Turiso, PhD, Team Leader, Medicinal Chemistry, Drug Discovery, Biogen

Targeting CDK Protein by Covalent Inhibitor and PROTAC Degrader

Tinghu Zhang, Scientist, Nathanael Gray Lab, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

TARGETED KINASE DEGRADATION STRATEGIES


New Activities for Cereblon Modulators

Philip Chamberlain, DPhil, Executive Director, Structural and Chemical Biology, Celgene

So Many Ubiquitin Ligases and So Few PROTACs: Carving a New Path with Novel Ligases

Tauseef Butt, PhD, President and CEO, Progenra Inc.

Molecular Mechanisms of Small Molecule-Mediated Ubiquitin Ligase Targeting

Eric S. Fischer, PhD, Assistant Professor, Cancer Biology/Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute/Harvard Medical School

Targeting Focal Adhesion Kinase with PROTACs: From Tool to in Vivo

Joao Nunes, PhD, Investigator, Protein Degradation Group, Medicinal Science and Technology, GSK Medicine Research Centre

ADME Properties of PROTACs and Oral Bioavailability Improvement Strategies

Upendra Dahal, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated
2019/10/31
Agenda,Sponsor updated